LYEL
Lyell Immunopharma, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Fund move
Fund move
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Lyell Immunopharma, Inc.
10.96
−0.34 · −3.03%
post 10.96 0.00%
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Arch VentureArch Venture | $45.5M | 26.89% | 0.00% | |
| 2 | GlaxosmithklineGlaxosmithkline | $21.3M | 12.55% | 0.00% | |
| 3 | Vanguard Capital ManagementVanguardindex-like | $11.1M | 6.53% | +9.55% | |
| 4 | Orland PropertiesOrland Properties | $10.6M | 6.26% | 0.00% | |
| 5 | BlackRockBlackRockindex-like | $10.2M | 6.01% | +277.62% | |
| 6 | Almitas CapitalAlmitas Capital | $8.2M | 4.82% | +0.62% | |
| 7 | Foresite Capital Management VForesite Capital Management V | $6.7M | 3.95% | −0.15% | |
| 8 | Millennium ManagementMillennium | $5.2M | 3.05% | −19.92% | |
| 9 | Opaleye ManagementOpaleye | $4.8M | 2.85% | +334.94% | |
| 10 | venBio PartnersvenBio Partners | $4.7M | 2.80% | 0.00% | |
| 11 | Geode Capital ManagementGeodeindex-like | $4.4M | 2.58% | +86.03% | |
| 12 | AlphabetAlphabet | $4.1M | 2.43% | 0.00% | |
| 13 | State StreetState Streetindex-like | $2.6M | 1.54% | +155.54% | |
| 14 | SC China HoldingSC China | $2.1M | 1.26% | 0.00% | |
| 15 | Renaissance TechnologiesRenaissance Technologies | $1.8M | 1.08% | +11.84% | |
| 16 | Northern TrustNorthern Trustindex-like | $1.7M | 0.98% | +291.35% | |
| 17 | Qube Research & TechnologiesQube Research & Technologies | $1.6M | 0.92% | +100.56% | |
| 18 | Charles Schwab Investment ManagementCharles Schwabindex-like | $1.5M | 0.89% | +25.12% | |
| 19 | Marshall WaceMarshall Wace | $1.5M | 0.88% | −28.43% | |
| 20 | Velan Capital Investment ManagementVelan Capital | $1.5M | 0.87% | +2.94% | |
| 21 | Vanguard Fiduciary TrustVanguard Fiduciary Trustindex-like | $1.3M | 0.77% | new | |
| 22 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $1.3M | 0.76% | +299.27% | |
| 23 | MIC Capital Management UKMIC Capital Management UK | $1.2M | 0.72% | 0.00% | |
| 24 | Goldman Sachs GroupGoldman Sachs | $1.2M | 0.72% | −24.20% | |
| 25 | Dimensional Fund AdvisorsDimensional | $957,066 | 0.57% | +42.66% |
87 managers report $169.3M of Lyell Immunopharma on form 13F for the quarter ended Jun 30 '26. 12 of them hold 80% of it; Arch Venture is largest at 26.89%.
Expected move
Inputsspot 11.04exp Nov 20ATM strike 11ATM straddle 5.00IV 240%